{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:07:20Z","timestamp":1769108840238,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010294","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000}}],"reference-count":132,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010294.pub2","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T13:41:34Z","timestamp":1436881294000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interventions for preventing the progression of autosomal dominant polycystic kidney disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Davide","family":"Bolignano","sequence":"first","affiliation":[{"name":"CNR - Italian National Council of Research; Institute of Clinical Physiology; CNR-IFC Via Vallone Petrara c\/o Ospedali Riuniti Reggio Calabria Italy 89100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Via Solaroli 17 Novara Italy 28100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[{"name":"CNR - Italian National Council of Research; Institute of Clinical Physiology; CNR-IFC Via Vallone Petrara c\/o Ospedali Riuniti Reggio Calabria Italy 89100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"Diaverum Academy; Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Apperloo","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Curren","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00019053-200220010-00004","article-title":"Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation","volume":"20","author":"Hogan","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0004|cit4","first-page":"S63","article-title":"Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"63","author":"Locatelli","year":"1997","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1046\/j.1523-1755.2000.07507.x","article-title":"The role of underlying nephropathy in the progression of renal disease","volume":"75","author":"Locatelli","year":"2000","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010294.pub2-BIB0006|cit6","first-page":"S39","article-title":"Perspectives of ACE inhibition in progressive renal failure [abstract]","volume":"3","author":"Mann","year":"1997","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0007|cit7","unstructured":"Maschio G Alberti D Janin G Locatelli F Mann J Motolese M The use of benazepril in the treatment of progressive renal disease [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 65"},{"issue":"15","key":"10.1002\/14651858.CD010294.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00005344-199900001-00004","article-title":"Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group","volume":"33 Suppl 1","author":"Maschio","year":"1999","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD010294.pub2-BIB0011|cit11","first-page":"S159","article-title":"Economic evaluation of benazepril in chronic renal insufficiency","volume":"52","author":"Hout","year":"1997","journal-title":"Kidney International - Supplement"},{"issue":"9903","key":"10.1002\/14651858.CD010294.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010294.pub2-BIB0013|cit13","first-page":"S338","article-title":"Clinical observation on adult polycystic kidney disease treated with calcitriol and 'qijudihuang mixt' [abstract no: P1057]","volume":"3","author":"Biao","year":"1997","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2005.01.001","article-title":"Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD)","volume":"26","author":"Cadnapaphornchai","year":"2005","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2005.01.001","article-title":"Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD)","volume":"26","author":"Cadnapaphornchai","year":"2005","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2005.01.001","article-title":"Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD)","volume":"26","author":"Cadnapaphornchai","year":"2005","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(00)70195-8","article-title":"Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"35","author":"Ecder","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/ndt\/14.5.1113","article-title":"Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"14","author":"Ecder","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD010294.pub2-BIB0022|cit22","first-page":"534A","article-title":"Reversal of left ventricular hypertrophy in autosomal dominant polycystic kidney disease (ADPKD) patients with rigorous blood pressure (BP) control [abstract]","volume":"12","author":"Ecder","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD010294.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0024|cit24","first-page":"246","article-title":"Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial","volume":"12","author":"Chrispijn","year":"2011","journal-title":"Trials [Electronic Resource]"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010294.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/S0168-8278(13)61385-9","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial in polycystic liver disease patients [abstract]","volume":"58","author":"Chrispijn","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD010294.pub2-BIB0028|cit28","first-page":"375A","article-title":"Randomised controlled trial of HMG CO A reductase inhibitor in polycystic renal disease in man [abstract no: A1733]","volume":"8","author":"Kincaid-Smith","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/ndt\/gfn144","article-title":"The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD","volume":"23","author":"Higashihara","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010294.pub2-BIB0030|cit30","first-page":"328A","article-title":"OctreotideLAR inhibits hepatorenal cystogenesis in the human polycystic liver diseases","volume":"50","author":"Hogan","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD010294.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010294.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8278(10)60068-2","article-title":"Growth of liver volume stops after one year of lanreotide in patients with polycystic livers","volume":"52","author":"Chrispijn","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010294.pub2-BIB0035|cit35","first-page":"328A","article-title":"Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial [abstract]","volume":"50","author":"Keimpema","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0037|cit37","first-page":"i81","article-title":"Efficacy and safety of sirolimus in reducing cyst volume in patients with autosomal dominant polycystic kidney disease [abstract]","volume":"28","author":"Melemadathil","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0038|cit38","first-page":"1492","article-title":"Use of rapamycin to reduce the pathologic kidney volume growth in autosomal polycystic kidney disease [abstract]","volume":"28","author":"Mora","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000045963","article-title":"Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease","volume":"88","author":"Nakamura","year":"2001","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000045963","article-title":"Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease","volume":"88","author":"Nakamura","year":"2001","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000045963","article-title":"Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease","volume":"88","author":"Nakamura","year":"2001","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MAJ.0b013e31821f0552","article-title":"Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension","volume":"343","author":"Nakamura","year":"2012","journal-title":"American Journal of the Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0043|cit43","first-page":"c18","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010294.pub2-BIB0044|cit44","first-page":"ii46","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010294.pub2-BIB0046|cit46","first-page":"ii46","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010294.pub2-BIB0048|cit48","first-page":"ii46","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (ADPKD) study: a randomized, controlled study [abstract]","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD010294.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD010294.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2936-9","DOI":"10.1016\/j.transproceed.2012.06.073","article-title":"Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment","volume":"44","author":"Soliman","year":"2012","journal-title":"Transplantation Proceedings"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD010294.pub2-BIB0055|cit54","first-page":"123A","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease - a pilot study [abstract no: TH-PO053]","volume":"19","author":"Soliman","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0054|cit55","doi-asserted-by":"crossref","first-page":"3639-41","DOI":"10.1016\/j.transproceed.2009.05.032","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study","volume":"41","author":"Soliman","year":"2009","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD010294.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"e45868","DOI":"10.1371\/journal.pone.0045868","article-title":"Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD Trial","volume":"7","author":"Braun","year":"2012","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"11","key":"10.1002\/14651858.CD010294.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMc1113145","article-title":"Ovarian toxicity from sirolimus","volume":"366","author":"Braun","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 167","key":"10.1002\/14651858.CD010294.pub2-BIB0058|cit58","first-page":"4S","article-title":"Safety, tolerability and adherence of sirolimus in autosomal dominant polycystic kidney disease [abstract no: 2.5]","volume":"138","author":"Serra","year":"2008","journal-title":"Swiss Medical Weekly"},{"issue":"11","key":"10.1002\/14651858.CD010294.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1093\/ndt\/gfp280","article-title":"Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease","volume":"24","author":"Serra","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0062|cit62","unstructured":"Serra AL Poster D Kistler AD Wuthrich RP Interim analysis of efficacy, safety and tolerability of sirolimus in patients with autosomal dominant polycystic kidney disease (ADPKD) [abstract no: SA064] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/S0168-8278(12)61406-8","article-title":"The reduction in liver volume in polycystic liver disease with lanreotide is dose dependent and is most pronounced in patients with the highest liver volume [abstract]","volume":"56","author":"Temmerman","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0064|cit64","first-page":"68A","article-title":"A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA), in patients with ADPKD [abstract no: F-FC139]","volume":"16","author":"Chapman","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"October","key":"10.1002\/14651858.CD010294.pub2-BIB0065|cit65","first-page":"361A","article-title":"Acute and chronic osmostasis after vasopressin V2 receptor inhibition with tolvaptan in ADPKD [abstract no: F-PO106]","volume":"16","author":"Grantham","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"October","key":"10.1002\/14651858.CD010294.pub2-BIB0066|cit66","first-page":"361A","article-title":"Urine aquaporin 2 and cyclic AMP responses to tolvaptan administration in autosomal dominant polycystic kidney disease [abstract no: F-PO108]","volume":"16","author":"Torres","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD010294.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0068|cit68","first-page":"361A","article-title":"Phase 2 open-label study to determine safety, tolerability and efficacy of split-dose tolvaptan in ADPKD [abstract no: SA-PO077]","volume":"18","author":"Torres","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010294.pub2-BIB0069|cit69","first-page":"iii6","article-title":"Urine osmolality and outcome in ADPKD: Results from the TEMPO 3:4 trial [abstract]","volume":"29","author":"Devuyst","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"25","key":"10.1002\/14651858.CD010294.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010294.pub2-BIB0071|cit71","first-page":"iii6","article-title":"Tolvaptan-treatment of ADPKD confers persistent EGFR improvement: Results from the TEMPO 4:4 extension trial [abstract]","volume":"29","author":"Torres","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study","volume":"57","author":"Torres","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/0886022X.2010.502277","article-title":"A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"32","author":"Ulusoy","year":"2010","journal-title":"Renal Failure"},{"issue":"11","key":"10.1002\/14651858.CD010294.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"Dijk","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD010294.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease","volume":"18","author":"Dijk","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD010294.pub2-BIB0077|cit77","first-page":"428A","article-title":"A long-term comparison of the effects of renal function of BP control with either atenolol (A) or enalapril (E) in polycystic kidney disease (PKD) [abstract]","volume":"10","author":"Watson","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD010294.pub2-BIB0078|cit78","first-page":"109A","article-title":"Determinants for the treatment of hypertensive patients with autosomal dominant polycystic kidney disease (ADPKD): choice of drug versus blood pressure (BP) control [abstract]","volume":"14","author":"Mueller","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ndt\/gfm731","article-title":"Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease","volume":"23","author":"Zeltner","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.hjh.0000222765.30348.0d","article-title":"The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients","volume":"24","author":"Doulton","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0081|cit81","unstructured":"O'Shaugnessy K A rotation study through the main therapeutic classes of antihypertensive in patients with polycystic kidney disease and hypertension controlled-trials.com\/ISRCTN57653760"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/oxfordjournals.qjmed.a030139","article-title":"Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease","volume":"89","author":"Kanno","year":"1996","journal-title":"Qjm"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0083|cit83","first-page":"568","article-title":"Renal protective effects of calcium channel blocker on hypertensive patients with autosomal dominant polycystic kidney disease [abstract]","volume":"5","author":"Suzuki","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00000441-200510000-00002","article-title":"Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease","volume":"330","author":"Nakamura","year":"2005","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0085|cit85","first-page":"126","article-title":"Magnetic resonance based studies as a marker of disease progression in autosomal-dominant polycystic kidney disease and the effect of simvastatin on disease progression [abstract]","volume":"14","author":"Sharma","year":"2004","journal-title":"Indian Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cct.2011.01.008","article-title":"Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants","volume":"32","author":"Cadnapaphornchai","year":"2011","journal-title":"Contemporary Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0090|cit89","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2215\/CJN.00060108","article-title":"Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies","volume":"3","author":"Chapman","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0089|cit90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD010294.pub2-BIB0091|cit91","first-page":"123A","article-title":"Impact of autosomal dominant polycystic kidney disease on quality of life: results from the HALT-PKD study [abstract no: TH-PO052]","volume":"19","author":"Miskulin","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","article-title":"Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study","volume":"63","author":"Miskulin","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD010294.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2215\/CJN.04610511","article-title":"Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease","volume":"6","author":"Perrone","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MBP.0b013e328344c6f3","article-title":"Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease","volume":"16","author":"Rahbari-Oskoui","year":"2011","journal-title":"Blood Pressure Monitoring"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0095|cit95","first-page":"361A","article-title":"Design of the HALT-PKD studies [abstract no: F-PO105]","volume":"16","author":"Schrier","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"24","key":"10.1002\/14651858.CD010294.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD010294.pub2-BIB0097|cit97","first-page":"837A","article-title":"The HALT-PKD trials: selection of novel endpoints and study update [abstract no: PUB023]","volume":"18","author":"Steinman","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"24","key":"10.1002\/14651858.CD010294.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010294.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney International"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD010294.pub2-BIB0100|cit100","first-page":"123A","article-title":"Achievement and maintenance of blood pressure targets in HALT-PKD [abstract no: TH-PO051]","volume":"19","author":"Torres","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0101|cit101","unstructured":"NCT01233869 A phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety, clinical activity and pharmacokinetics of bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD) www.clinicaltrials.gov\/ct2\/show\/NCT01233869 2014 9407447"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13063-015-0692-3","article-title":"Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial","volume":"16","author":"Riegersperger","year":"2015","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and design of the DIPAK 1 Study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Meijer","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0104|cit104","unstructured":"NCT00345137 Phase 1 study of systemic effects of Ng-monomethyl-L-arginine on renal hemodynamics in patients with polycystic kidney disease and chronic glomerulonephritis www.clinicaltrials.gov\/ct2\/show\/NCT00345137"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0105|cit105","unstructured":"NCT01932450 A randomized, open-label study investigating the effect of bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on blood pressure and disease progression in autosomal dominant polycystic kidney disease www.clinicaltrials.gov\/ct2\/show\/NCT01932450 2013"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000334166","article-title":"Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects","volume":"120","author":"Chang","year":"2012","journal-title":"Nephron Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573402111309010002","article-title":"Cardiovascular complications in autosomal dominant polycystic kidney disease","volume":"9","author":"Ecder","year":"2013","journal-title":"Current Hypertension Reviews"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0108|cit108","unstructured":"ERA-EDTA Registry ERA-EDTA Registry Annual Report 2011. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2011 www.era-edta-reg.org\/files\/annualreports\/pdf\/AnnRep2011.pdf"},{"issue":"10","key":"10.1002\/14651858.CD010294.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1323-6","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","article-title":"Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat","volume":"26","author":"Gile","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"20","key":"10.1002\/14651858.CD010294.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2122-30","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"108-16","DOI":"10.1038\/sj.ki.5002624","article-title":"Determinants of renal volume in autosomal-dominant polycystic kidney disease","volume":"73","author":"Grantham","year":"2008","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1010845","article-title":"mTOR inhibitors and autosomal dominant polycystic kidney disease","volume":"364","author":"Grantham","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010294.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annual Review of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000341263","article-title":"Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment","volume":"36","author":"Helal","year":"2012","journal-title":"American Journal of Nephrology"},{"issue":"7414","key":"10.1002\/14651858.CD010294.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0118|cit118","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2019,5\u2019-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD010294.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1523-1755.2000.00835.x","article-title":"Modification of polycystic kidney disease and fatty acid status by soy protein diet","volume":"57","author":"Ogborn","year":"2000","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.2005070697","article-title":"Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort","volume":"17","author":"Rule","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD010294.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","article-title":"Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Schrier","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9569","key":"10.1002\/14651858.CD010294.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010294.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD010294.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD010294.pub2-BIB0128|cit128","unstructured":"Table A.1.7 Incident counts of reported ESRD: all patients by age, gender, race, ethnicity, & primary diagnosis. IN: US Renal Data Services. Table A.1, Incident counts of reported ESRD: all patients www.usrds.org\/2008\/ref\/A_incidence_08.pdf"},{"issue":"3","key":"10.1002\/14651858.CD010294.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD010294.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney & Blood Pressure Research"},{"issue":"5","key":"10.1002\/14651858.CD010294.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000254338","article-title":"Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy","volume":"32","author":"W\u00fcthrich","year":"2009","journal-title":"Kidney & Blood Pressure Research"},{"issue":"1","key":"10.1002\/14651858.CD010294.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010294","article-title":"Interventions for preventing the progression of autosomal dominant polycystic kidney disease","author":"Bolignano","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010294.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010294.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:19:36Z","timestamp":1647101976000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010294.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":132,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010294.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010294.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}